NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.786
-0.023 (-2.87%)
Apr 29, 2026, 3:10 PM EDT - Market open
NeuroSense Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -11.13 | -10.21 | -10.11 | -10.49 | -3.22 | |
| Depreciation & Amortization | 0.02 | 0.02 | 0.02 | 0.01 | 0 | |
| Loss (Gain) From Sale of Assets | - | - | - | - | 0.01 | |
| Stock-Based Compensation | 2.14 | 0.56 | 1.54 | 1.73 | 1.22 | |
| Other Operating Activities | -0.05 | 0.28 | -1.72 | 0.04 | 0.18 | |
| Change in Accounts Payable | -0.36 | -0.3 | 0.96 | 0.46 | -0.02 | |
| Change in Other Net Operating Assets | 1.71 | -0.48 | 0.95 | 0.64 | 0.29 | |
| Operating Cash Flow | -7.67 | -10.14 | -8.35 | -7.62 | -1.54 | |
| Capital Expenditures | -0.01 | -0 | -0.03 | -0.07 | -0.02 | |
| Investment in Securities | - | - | 3.5 | -3.5 | - | |
| Other Investing Activities | - | 0 | -0 | -0.02 | - | |
| Investing Cash Flow | -0.01 | 0 | 3.47 | -3.59 | -0.02 | |
| Issuance of Common Stock | 4.55 | 11.3 | 4.34 | 3.87 | 11.9 | |
| Other Financing Activities | -0.12 | -0.39 | -0.36 | -0.1 | - | |
| Financing Cash Flow | 4.43 | 10.91 | 3.98 | 3.77 | 11.9 | |
| Foreign Exchange Rate Adjustments | 0.04 | -0.04 | 0.01 | -0.09 | 0.02 | |
| Net Cash Flow | -3.21 | 0.74 | -0.9 | -7.52 | 10.36 | |
| Free Cash Flow | -7.68 | -10.14 | -8.38 | -7.69 | -1.56 | |
| Free Cash Flow Per Share | -0.30 | -0.55 | -0.61 | -0.67 | -0.25 | |
| Levered Free Cash Flow | -3.87 | -7.83 | -4.26 | -3.8 | -0.47 | |
| Unlevered Free Cash Flow | -3.87 | -7.83 | -4.26 | -3.8 | -0.47 | |
| Change in Working Capital | 1.34 | -0.78 | 1.91 | 1.1 | 0.27 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.